DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis and a high frequency of central nervous system relapse after standard immunochemotherapy. We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednis...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Kana, Asano, Naoko, Yamada, Tomomi, Miyawaki, Kohta, Sakai, Rika, Igarashi, Tadahiko, Nishikori, Momoko, Ohata, Kinya, Sunami, Kazutaka, Yoshida, Isao, Yamamoto, Go, Takahashi, Naoki, Okamoto, Masataka, Yano, Hiroki, Nishimura, Yuki, Tamaru, Satoshi, Nishikawa, Masakatsu, Izutsu, Koji, Kinoshita, Tomohiro, Suzumiya, Junji, Ohshima, Koichi, Kato, Koji, Katayama, Naoyuki, Yamaguchi, Motoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556618/
https://www.ncbi.nlm.nih.gov/pubmed/33054055
http://dx.doi.org/10.3324/haematol.2019.231076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556618/
https://www.ncbi.nlm.nih.gov/pubmed/33054055
http://dx.doi.org/10.3324/haematol.2019.231076

Ejemplares similares